viewCanntab Therapeutics Ltd

Canntab Therapeutics extends its intellectual property portfolio

The company recently made three additional US patent applications and one international patent application

Bag of pot
The company is developing pharmaceutical preparations that contain natural or synthetic cannabinoids

Canntab Therapeutics Ltd (CNSX:PILL) has now filed 11 patents related to pharmaceutical cannabis.

These filings, which include seven non-provisional United States patent applications and four patent co-operation treaty (PCT) patent applications, build on Canntab's growing intellectual property portfolio.

READ Pot pill maker Canntab Therapeutics debuts on Canadian exchange, shares pop​

These patent applications are part of Canntab's concerted strategy to develop a comprehensive intellectual property portfolio that covers the company's technology and formulations related to pharmaceutical preparations that contain natural or synthetic cannabinoids.

Canntab is currently developing a number of products that use this technology, which includes a variety of extended released tablets containing a mixture of THC (tetrahydrocannabinol) and CBD (cannabidiol) that can be used to treat a number of ailments, such as sleep disorders, post-traumatic stress disorder (PTSD), social anxiety, addiction, arthritis, general pain, and the pain management and appetite loss associated with cancer treatments.

The company is currently awaiting a decision from Health Canada on its extended release tablets and is making batches of the tablets for third party clinical trials in Canada.


Quick facts: Canntab Therapeutics Ltd

Price: 0.66 CAD

Market: CSE
Market Cap: $20.77 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Canntab Therapeutics Ltd named herein, including the promotion by the Company of Canntab Therapeutics Ltd in any Content on the Site, the...



Full interview: Canntab Therapeutics gets first commercial sale with Medipharm

Canntab Therapeutics (CSE: PILL- OTCQB: CTABF) CFO Richard Goldstein and Special Advisor Larry Latowsky joined Steve Darling from Proactive Vancouver with news the company has signed their first contract for their slow release tablets with MediPharm.  Goldstein discusses how the...

on 2/6/20

2 min read